Heme deficiency in skeletal muscle exacerbates sarcopenia and impairs autophagy by reducing AMPK signaling
Heme serves as a prosthetic group in hemoproteins, including subunits of the mammalian mitochondrial electron transfer chain. The first enzyme in vertebrate heme biosynthesis, 5-aminolevulinic acid synthase 1 (ALAS1), is ubiquitously expressed and essential for producing 5-aminolevulinic acid (ALA). We previously showed that Alas1 heterozygous mice at 20-35 weeks (aged-A1<sup>+/-</sup>s) manifested impaired glucose metabolism, mitochondrial malformation in skeletal muscle, and reduced exercise tolerance, potentially linked to autophagy dysfunction. In this study, we investigated autophagy in A1<sup>+/-</sup>s and a sarcopenic phenotype in A1<sup>+/-</sup>s at 75-95 weeks (senile-A1<sup>+/-</sup>s). Senile-A1<sup>+/-</sup>s exhibited significantly reduced body and gastrocnemius muscle weight, and muscle strength, indicating an accelerated sarcopenic phenotype. Decreases in total LC3 and LC3-II protein and Map1lc3a mRNA levels were observed in aged-A1<sup>+/-</sup>s under fasting conditions and in Alas1 knockdown myocyte-differentiated C2C12 cells (A1KD-C2C12s) cultured in high- or low-glucose medium. ALA treatment largely reversed these declines. Reduced AMP-activated protein kinase (AMPK) signaling was associated with decreased autophagy in aged-A1<sup>+/-</sup>s and A1KD-C2C12s. AMPK modulation using AICAR (activator) and dorsomorphin (inhibitor) affected LC3 protein levels in an AMPK-dependent manner. Our findings suggest that heme deficiency contributes to accelerated sarcopenia-like defects and reduced autophagy in skeletal muscle, primarily due to decreased AMPK signaling.
Authors
- Shinichi Saitoh (ORCID: https://orcid.org/0000-0001-7523-8177)
- Michiaki Takagi (ORCID: https://orcid.org/0000-0002-3052-787X)
- Motowo Nakajima (ORCID: https://orcid.org/0000-0001-7687-6365)
- Satoshi Okano (ORCID: https://orcid.org/0000-0003-1272-4981)
- Koen van Wijk (ORCID: https://orcid.org/0009-0006-0008-025X)
- Takeru Akabane (ORCID: https://orcid.org/0009-0008-9656-3532)
- Tohru Tanaka (ORCID: https://orcid.org/0000-0001-7175-0114)
- Osamu Nakajima (ORCID: https://orcid.org/0000-0001-9352-2446)
- Kiwamu Takahashi
- Ken Kodama (ORCID: https://orcid.org/0000-0002-2508-9449)
- Tomohiro Kimura (ORCID: https://orcid.org/0000-0003-0361-4633)
- Hiromori Sagae
Institutions
- Yamagata University (JP)
- SBI Pharmaceuticals (Japan) (JP)
- EA Pharma (Japan) (JP)
Publication Details
- Journal
- Scientific Reports
- Published
- 2024-09-27
- DOI
- https://doi.org/10.1038/s41598-024-73049-9
- Citations
- 5
- Primary Topic
- Autophagy in Disease and Therapy
- Type
- article
- Field-Weighted Citation Impact
- 1.93
Funders
- Japan Society for the Promotion of Science